Literature DB >> 3056533

E. coli infections of the lower urinary tract and their treatment by immunomodulation or combined immunomodulation and antigen therapy.

D Mathieu1, L Jacques, J Auer, B Bizzini.   

Abstract

A model of infection by E. coli 022 of the lower urinary tract in the rat is described. The infection is characterized by the presence in the urine of a large number of E. coli (10(5)-10(7) bacteria per ml). There is pus formation in the urine. A few infected rats also exhibited prostate hypertrophy and the presence of ACB could be detected in some of the latter group. Treatment of the infected rats by the C. granulosum-derived immunomodulator P40, injected intravenously either as a single dose of 1 mg per rat 1 day after infection or as 2 fractionated doses of 0.5 mg 1 day and 3 days after infection resulted in sterilization of a significant number of urines. The interest of fractionating the dose of P40 is to reduce the incidence of prostate hypertrophy formation. Comparable results were obtained when P40 was given preventively to the rats either as a single dose 7 days before infection or as 2 fractionated doses 7 days and 1 day before infection. The association of a single preventive dose of 1 mg of P40 given 7 days before infection by administering a suspension of heat-killed E. coli 022, as a specific antigen, 1 day after infection permitted the sterilization of urines in all infected rats and prostate hypertrophy formation did not occur.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3056533

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  1 in total

1.  Evaluation of hyaluronic acid-P40 conjugated cream in a mouse model of dermatitis induced by oxazolone.

Authors:  Katia Mangano; Franca Vergalito; Santa Mammana; Andrea Mariano; Rocco De Pasquale; Antonia Meloscia; Silvia Bartollino; Germano Guerra; Ferdinando Nicoletti; Roberto Di Marco
Journal:  Exp Ther Med       Date:  2017-07-19       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.